📊 AGIO Key Takeaways
Is Agios Pharmaceuticals, Inc.. (AGIO) a Good Investment?
Agios is a pre-profitability pharmaceutical company with positive revenue growth (48% YoY) but massive operating losses (-$110M on $20.7M revenue) and a tight cash runway of approximately 1 year at current burn rates. While the balance sheet is structurally sound with minimal debt and $1.1B equity, negative operating cash flow of -$118.9M indicates the company is unsustainable at its current trajectory without significant revenue acceleration or cost reduction.
Agios shows meaningful top-line growth and an exceptionally strong balance sheet, with high liquidity, no long-term debt, and substantial equity support. However, the business remains deeply unprofitable, with extremely negative operating and net margins and heavy cash burn that materially weakens growth quality. Fundamentally, this looks like a financially secure but still high-risk development-stage profile that needs much better operating leverage before warranting a more positive view.
Agios Pharmaceuticals, Inc.. Key Strengths (AGIO)
- Strong balance sheet with $1.1B stockholders equity and zero long-term debt
- Excellent liquidity position with 14.19x current ratio and $113.6M cash
- Positive revenue growth of 48% YoY demonstrates commercial traction
- Low leverage (0.00x debt-to-equity) provides financial flexibility
- Revenue grew 48.0% year over year, indicating commercial or collaboration momentum
- Balance sheet is very strong with $1.19B in equity, low liabilities, and no meaningful debt
- Liquidity is excellent, with current and quick ratios above 11x providing runway flexibility
AGIO Stock Risks: Agios Pharmaceuticals, Inc.. Investment Risks
- Severe cash burn of -$118.9M operating cash flow vs. $20.7M revenue creates ~1 year runway
- Operating losses of -$110M on minimal revenue indicate far from profitability inflection
- Negative and worsening EPS (-$1.69, -161.2% YoY) signals deteriorating financial performance
- High R&D and development costs suggest significant additional capital may be required
- Small revenue base suggests limited approved products or early commercialization phase with execution risk
- Operating losses are extremely large relative to revenue, with operating margin of -873.9%
- Free cash flow is deeply negative at -$377.29M, indicating ongoing cash burn
- Net income deteriorated sharply year over year, suggesting worsening profitability despite revenue growth
Key Metrics to Watch
- Quarterly revenue growth rate and gross margin improvement
- Operating cash flow trajectory and path to positive cash generation
- Cash and equivalents balance and estimated runway to profitability
- Pipeline advancement and clinical trial progress for key programs
- Operating expense trends and efficiency improvements
- Quarterly operating cash burn and free cash flow trend
- Revenue durability versus improvement in operating loss and net margin
Agios Pharmaceuticals, Inc.. (AGIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.19x current ratio provides a solid financial cushion.
AGIO Profit Margin, ROE & Profitability Analysis
AGIO vs Healthcare Sector: How Agios Pharmaceuticals, Inc.. Compares
How Agios Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Agios Pharmaceuticals, Inc.. Stock Overvalued? AGIO Valuation Analysis 2026
Based on fundamental analysis, Agios Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Agios Pharmaceuticals, Inc.. Balance Sheet: AGIO Debt, Cash & Liquidity
AGIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Agios Pharmaceuticals, Inc..'s revenue has declined by 73% over the 5-year period, indicating business contraction. The most recent EPS of $-6.33 indicates the company is currently unprofitable.
AGIO Revenue Growth, EPS Growth & YoY Performance
AGIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.7M | -$89.3M | $-1.55 |
| Q3 2025 | $9.0M | -$81.5M | $-1.78 |
| Q2 2025 | $8.6M | -$81.5M | $-1.69 |
| Q1 2025 | $8.2M | -$81.5M | $-1.45 |
| Q3 2024 | $7.4M | -$81.0M | $-1.64 |
| Q2 2024 | $6.7M | -$81.0M | $-1.51 |
| Q1 2024 | $5.6M | -$81.0M | $-1.45 |
| Q3 2023 | $3.5M | -$81.0M | $-1.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Agios Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
AGIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Agios Pharmaceuticals, Inc.. (CIK: 0001439222)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AGIO
What is the AI rating for AGIO?
Agios Pharmaceuticals, Inc.. (AGIO) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AGIO's key strengths?
Claude: Strong balance sheet with $1.1B stockholders equity and zero long-term debt. Excellent liquidity position with 14.19x current ratio and $113.6M cash. ChatGPT: Revenue grew 48.0% year over year, indicating commercial or collaboration momentum. Balance sheet is very strong with $1.19B in equity, low liabilities, and no meaningful debt.
What are the risks of investing in AGIO?
Claude: Severe cash burn of -$118.9M operating cash flow vs. $20.7M revenue creates ~1 year runway. Operating losses of -$110M on minimal revenue indicate far from profitability inflection. ChatGPT: Operating losses are extremely large relative to revenue, with operating margin of -873.9%. Free cash flow is deeply negative at -$377.29M, indicating ongoing cash burn.
What is AGIO's revenue and growth?
Agios Pharmaceuticals, Inc.. reported revenue of $20.7M.
Does AGIO pay dividends?
Agios Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find AGIO SEC filings?
Official SEC filings for Agios Pharmaceuticals, Inc.. (CIK: 0001439222) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AGIO's EPS?
Agios Pharmaceuticals, Inc.. has a diluted EPS of $-1.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is AGIO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Agios Pharmaceuticals, Inc.. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is AGIO stock overvalued or undervalued?
Valuation metrics for AGIO: ROE of -8.9% (sector avg: 15%), net margin of -477.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is AGIO's AI grade for 2026?
Our dual AI analysis gives Agios Pharmaceuticals, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AGIO's free cash flow?
Agios Pharmaceuticals, Inc..'s operating cash flow is $-118.9M, with capital expenditures of $769.0K. FCF margin is -576.9%.
How does AGIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -477.7% (avg: 12%), ROE -8.9% (avg: 15%), current ratio 14.19 (avg: 2).